


# SUPPORTING INFORMATION

## Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC


Soumavo Mukherjee <sup>1</sup>, Dhananjay Suresh <sup>1</sup>, Ajit Zambre <sup>2</sup>, Sairam Yadavilli <sup>1</sup>, Shreya Ghoshdastidar <sup>1</sup>, Anandhi Upendran <sup>3</sup> and Raghuraman Kannan <sup>1,2,4,\*</sup>

- 1 Department of Bioengineering, University of Missouri, Columbia, MO 65211, USA  
2 Department of Radiology, University of Missouri, Columbia, MO 65212, USA  
3 Department of Medical Pharmacology & Physiology, University of Missouri, Columbia, MO 65212, USA  
4 Ellis Fischel Cancer Center, University of Missouri, Columbia, MO 65212, USA  
\* Correspondence: kannanr@health.missouri.edu

### SUPPORTING FIGURES



**Figure S1. Flow Cytometry.** Flow cytometry data for AXL and SHP2 (inactivated) expression in A549 cells before and after treatment with Dasatinib (DAS), or siAXL, or combination of both for 48 h. Results indicate a spike in AXL expression when SRC is inactivated and a spike in inactivated SHP2 when both AXL and SRC are co-inhibited.



**Figure S2.** *Fluorescence analysis.* Quantification of cytochrome-C fluorescence intensity in A549 cells before and after treatment with DAS or siAXL+DAS.